We found that the mutation rates of TTN, PCLO, RYR3, and LRP2 in human lung adenocarcinoma were 41%, 16%, 14% and 11%, respectively, but the mutation rates of other mutant genes were <10% (Figure 4A and Table 2). This evidence concerns the gene PCLO and lung adenocarcinoma.